ADMA Biologics to Participate in Raymond James Institutional Investor Conference

ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 1, 2021, at 10:50 a.m. ET.

Rhea-AI Summary

ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 1, 2021, at 10:50 a.m. ET. The event will be available via webcast on the company’s website and will be archived for 90 days. ADMA focuses on manufacturing and developing specialty plasma-derived biologics, with three FDA-approved products aimed at treating immunodeficient patients and preventing infectious diseases.

Argus Session date unavailable

-1.54% session move Open Argus

Details

News Market Reaction – ADMA

The recorded move for ADMA in the trading session of this news was -1.54%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on Monday, March 1, 2021, at 10:50 a.m. ET.

A webcast of the event will be available on the Company’s website at https://ir.admabiologics.com/events-webcasts and will be archived for 90 days following the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA Bio Centers subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:

Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:

Sam Martin
Managing Director, Argot Partners | 212-600-1902 | sam@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is ADMA Biologics participating in on March 1, 2021?

ADMA Biologics, Inc. will participate in a fireside chat at the Raymond James Institutional Investor Conference.

Who will represent ADMA Biologics at the conference?

Adam Grossman, President and CEO of ADMA Biologics, will represent the company.

What time is ADMA's presentation at the conference?

The presentation is scheduled for March 1, 2021, at 10:50 a.m. ET.

Where can I watch the ADMA Biologics conference webcast?

The webcast will be available on ADMA's website and archived for 90 days.

What FDA-approved products does ADMA Biologics manufacture?

ADMA Biologics manufactures ASCENIV™, BIVIGAM®, and NABI-HB® for immune deficiencies and infectious diseases.